Abcellera biologics inc.ABCL.US Overview

US StockHealthcare

(No presentation for ABCL)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

ABCL Overall Performance

ABCL AI Analysis & Strategy

ABCL Recent Performance

-0.35%

Abcellera biologics inc.

0.81%

Avg of Sector

-1.14%

S&P500

ABCL PowerScanner

ABCL Key Information

ABCL Valuation Metrics

ABCL Earnings Table

ABCL Profile

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.